Molecular imaging developer Avid Radiopharmaceuticals said PETNet Solutions, a subsidiary of Siemens Healthcare of Malvern, PA, has shipped the first dose of its florbetapir (F-18 AV-45) molecular imaging agent for visualizing beta-amyloid deposits in the brain.
Florbetapir is being evaluated in U.S. and European Union clinical studies of patients with suspected Alzheimer's disease or mild cognitive impairment. PETNet is currently manufacturing the agent at multiple U.S. facilities and will continue to expand production capabilities to support its clinical development, according to Avid of Philadelphia and PETNet of Knoxville, TN.
Related Reading
Siemens' PETNet offers free NaF-18, March 19, 2010
Siemens completes U.K. order, March 10, 2010
Siemens to supply NaF-18 via PETNet, March 8, 2010
Avid adds to executive team, September 9, 2009
Avid phase II results presented at Alzheimer's conference, July 14, 2009
Avid closes on financing, May 22, 2009
Copyright © 2010 AuntMinnie.com
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
